Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Neuropharmacology. 2017 Dec 9;136(Pt B):287–297. doi: 10.1016/j.neuropharm.2017.12.016

Figure 1.

Figure 1

The role of amylin in Alzheimer’s disease remains an open question. As reviewed in this paper, numerous studies show that amylin can misfold and aggregate, and can cause or exacerbate pathophysiological changes associated with AD [e.g., (Fu et al., 2012; Jhamandas et al., 2011; Jhamandas and Mactavish, 2012)]. However, other data indicate that exogenous administration of amylin receptor agonists can ameliorate AD symptoms [e.g., (Adler et al., 2014; Zhu et al., 2015; Zhu et al., 2017b)], suggesting that amylin-based pharmacotherapies may be useful in the treatment of AD. There are currently several gaps in the literature that limit our understanding of the effects of amylin in AD, a few of which are represented in the gray diamonds.